Script Data, Part 4 – A Tale of Two Drugs, Continued. – MNKD, SNY

An update in our ongoing examination of the performance of two recent drug launches from Sanofi (SNY). One is Toujeo, an injectable. The other is Mannkind‘s (MNKD) much hyped, beloved by retail investors, inhaled insulin Afrezza. These two drugs are both for the treatment of diabetes. Sanofi uses the same salesforce, who would be detailing the exact same doctors for both drugs. Can you spot the commercial flop? Remember folks, we are looking for “up and to the right”, we don’t want to see the patient flatlining.

Spot the dismal, pathetic, failure.

Can Jefferies’ resident Mannkind moron Shaunak Deepak? Just for fun we’ve extended out the Afrezza data for the full 23 weeks it has been on the market. Toujeo has only been on the market for four months as of the last sales update.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

Advertisements

Quick Take – Bye Bye Mark Ahn (GALE)

As tweeted last night by The Street.com’s Adam Feuerstein, the smug Mark Ahn is out at dreadful Galena Biopharmaceutical (GALE). Read more here.

The sell-side analysts whoring themselves out for banking business, like Needham’s moronic Chad Messer (read about him here and here) will now have to dust off the pads and kneel before newly promoted GALE CEO Mark Schwartz.

For those playing at home, the case to watch (or better yet send in an FOIA request) is:

In the Matter of Galena Biopharma, SEC File No. HO 12356 now known as  “In the Matter of Certain Stock Promotions”

No wonder the GALE-eediots have been so silent recently.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Galena and the Epsilon Sock Puppets – GALE

A number of comments have recently been submitted for approval to the recent posts on bio-dreck Galena Biopharma (GALE), by commenters “Don Petty” and “Bryce in TX“. [Similar comments have been posted to other articles on other site, like Seeking Alpha, by Don and Bryce as well.]

Both seem to be stubbornly stupid GALE bulls.

It turns out that all 6 comments are from the exact same email address and posted from the same ip address. Nice try.

Quick Take – The Uri Landesman Magical Mystery Tour (ECTE, NEOP)

Our good friend, and Mark Nordlicht‘s right hand man, Uri Landesman was back on the air this holiday-shortened week, discussing everyone’s favorite tired old bio-dreck, reverse merger company Echo Therapeutics (ECTE) and bucket shop IPO Neoprobe (NEOP). Read more about ECTE here, and a great piece on NEOP, by Martin Shkreli, here. And check out Uri’s performance!

Happy Holidays!

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

Congratulations Echo He! (HRBN)

In a surprise victory, beating out both Carol Wang and Henry Ai, with almost 50% of the vote, the winner of the most recent Weekend Poll, “Who is the next Ping Luo?” is Maxim Group’s Echo He.

Echo released a report on Harbin Electric (HRBN), a prototypical Chinese reverse-merger company, entitled “It’s not about trust, but common sense; Reiterate Buy.” News flash for Echo, it is only about trust. And simply put, there is not a single sell-side analyst that should be trusted blindly, not ones who work at Morgan Stanley or Goldman Sachs and certainly not ones that work at third-tier SPAC shops like Maxim.

Harbin is not Echo‘s only bizarre call.

Global Hunter: Morons or Mega-Morons?

This morning, top tier Chinese reverse-merger shop Global Hunter Securities issued a truly enlightening research report entitled “China: Margin of Safety Investing in China – Oxymoron or Moron?” At the end of the report is the following chart, reformatted for this post:

               Research Cov.         IB Clients
Rating      Count   % of Total   Count  % of Total
Buy           68       55.3%      15      60.0%              
Accumulate    21       17.1%       3      12.0%               
Neutral       28       22.8%       6      24.0%               
Reduce         5        4.1%       1       4.0%               
Sell           0          0%       0       0.0%                
NA             1        0.8%       0       0.0%                
Total        123        100%      25       100%

Not a single stock in their coverage universe, not one, is rated a “Sell.” Is it possible that the sharp minds, like Ping Luo, at GH have been unable to detect even one shady Chinese reverse-merger stock? Given that fraud is endemic to both the reverse merger space and China, it seems absurd that these folks believe over 70% of their universe is a buy or accumulate. Are they so blind, so greedy, or so complicit that none are outright sells?

Considering that Global Hunter is one of the shops that recommended both China Media Express (CCME) and RINO Intl (RINO) to clients, perhaps the better question for investors to ask is “Global Hunter: Morons or Mega-Morons?”

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

Best penny stock executive name, ever. (JCOF)

Hot on the heels of Shane Whittle’s Jammin Java (JAMN) promotion, see here and here, comes me-too coffee stock, Pink Sheet darling Javalution (JCOF). Javalution issued a press release on the 9th of May quoting founder and President Scott Pumper.

“We are delighted that our relationship with Richmont has now moved to a new level,” said Scott Pumper, Founder and President of Javalution. “Combining our expertise in the coffee industry with the strategic business and financial experience of John Rochon and his team gives us a great launching pad to broaden Javalution’s horizon. This is an important step in our growth.”

Fabulous.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.